Skip to main content
Fig. 5 | BMC Infectious Diseases

Fig. 5

From: Immunogenicity after outbreak response immunization activities among young healthcare workers with secondary vaccine failure during the measles epidemic in Korea, 2019

Fig. 5

Measles virus (MeV) IgG antibody avidity in each group according to measles immunity status. A MeV IgG antibody avidity at 1 month after MMR2. B MeV IgG antibody avidity at 6 months after MMR2. C Individual time-dependent MeV IgG avidity at 1 and 6 months after MMR2. Group 1: natural immunity; Group 2: vaccine-induced immunity; Group 3: vaccine failure, MMR: measles-mumps-rubella

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us